Content created by members of Rolling Stone Culture Council Rolling Stone Culture Council is an invitation-only network of industry professionals who share their insights with our audience.Opinions expressed are solely those of the author and do not reflect the views of Rolling Stone editors or publishers.
With a new era of medical cannabis here at last, it’s important for both established stakeholders and hopeful prospects to recognize which factors will serve as the catalysts for market growth and development and the factors that can pose limitations.Under reclassification, medical cannabis can be prescribed in the same manner as other prescription medications.
In 2016, Pennsylvania Governor Tom Wolf signed the compassionate medical cannabis legislation. Two years later, the first medical dispensary in Pennsylvania opened to allow patients to purchase cannabis as a prescribed medical treatment from their physician. According to the, initially, the only types of medical cannabis allowed were pills, oils, gels, creams, ointments, tinctures, liquid and non-whole plant forms for administration through vaporization.
Within less than two months since reclassification, patient numbers have already been growing multiple times, and compared to statistics from Florida and California — former medical markets before adult-use legalization — Germany has a potential of around 5 million cannabis patients.Currently, Germany relies on several countries, including its biggest supplier, Canada, as well as Portugal, the Netherlands, Denmark, Australia and Colombia, to supply its medical cannabis market.